AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is listed today as AN2 Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2026 | $40 M | Private placement after listing | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
AN2 Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2026).
SEC Form D · Mar 2026
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Mar 2026
That is all the official record says: AN2 Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of AN2 Therapeutics, Inc. are on record.
Investors#
9 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Adjuvant Capital GP, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Adjuvant Capital Management, LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Adjuvant Global Health Technology Fund DE, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Adjuvant Global Health Technology Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Eric Easom | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2022) | SEC Form 3 |
| Joseph S. Zakrzewski | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2022) | SEC Form 3 |
| RA Capital Healthcare Fund LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Ra Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| RA Capital Nexus Fund II, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding AN2 Therapeutics, Inc. shares, as of Sep 30, 2026.
- Vivo Capital, LLC$17 M8.31%
- Commodore Capital LP$16 M7.73%
- Millennium Management LLC$13 M6.53%
- BlackRock, Inc.$9 M4.67%
- Spruce Street Capital LP$9 M4.62%
- Acorn Capital Advisors, LLC$7 M3.43%
- Vanguard Capital Management LLC$7 M3.26%
- Adage Capital Partners GP, L.L.C.$5 M2.64%
- Citadel Advisors LLC$5 M2.59%
- Boxer Capital Management, LLC$5 M2.49%
- Geode Capital Management, LLC$4 M1.80%
- Goldman Sachs Group Inc$3 M1.67%
- Tetragon Partners GP Ltd$3 M1.59%
- SummitTX Capital, L.P.$3 M1.58%
- Sio Capital Management, LLC$3 M1.44%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Eric Easom | Executive officer | Mar 2026 |
| Joshua Eizen | Executive officer | Mar 2026 |
| Lucy Day | Executive officer | Mar 2026 |
| Sanjay Chanda | Executive officer | Mar 2026 |
| Eric Easom | Director | Mar 2026 |
| Gilbert Lynn Marks | Director | Mar 2026 |
| Joseph S. Zakrzewski | Director | Mar 2026 |
| Kabeer S. Aziz | Director | Mar 2026 |
| Margaret Lynn FitzPatrick | Director | Mar 2026 |
| Melvin Lynn Spigelman | Director | Mar 2026 |
| Patricia Lynn Martin | Director | Mar 2026 |
| Rob S. Readnour | Director | Mar 2026 |
| Stephanie Lynn Wong | Director | Mar 2026 |
Went public since 2022. Its SEC number is that of a company listed on a stock exchange.